Predictive and Presymptomatic Testing Market – Size, Outlook, Trends and Forecast (2024 – 2032)

Diagnostic testing is different from predictive and presymptomatic testing. A predictive and presymptomatic test is used in detecting associated gene disorders that might appear right after birth or in future. The presymptomatic test can identify whether an individual will develop that particular genetic disorder, far before any symptoms occur whereas, the predictive test is used to determine the risk of having disorders with a genetic basis, like various types of cancers.

Predictive & Presymptomatic Testing Market Segments Size & Growth:

Predictive & Presymptomatic Testing Market is accounted for $XX billion in 2017 and expected to grow at a CAGR of XX% to reach $XX billion by 2024 during the forecast period 2018-2024. Major factors that are driving the market growth an increase in genetic disorders, research in genomics and government regulations. However, high-cost test procedures hinder the growth of the predictive and presymptomatic testing market.

Predictive & Presymptomatic Testing Market Segments Share:

Predictive & Presymptomatic Testing Market is categorised into by condition which consists of breast and ovarian cancer, colorectal cancer, Alzheimer’s disease, and multiple endocrine neoplasia type2. Due to increase in genetic disorders and their related diseases largest share is among every condition related to gene mutations.

By Geography, North America is dominating the predictive and presymptomatic testing market, and the growth in North America is mainly attributed because of the increasing adoption of well-established healthcare facilities and research activities on genetics. Furthermore, Asia-Pacific is witnessing the fastest growth during the forecast period, due to rising ageing population, investments in research on genomics and awareness among people.

Predictive & Presymptomatic Testing Market Segments Trends:

• In September 2017, Quest Diagnostics Inc. has acquired Shiel Medical Laboratory to deliver high-quality healthcare to people with chronic diseases and renal conditions.
• In October 2017, Abbott Molecular Inc. has completed its acquisition of Alere to expand its firms.

Predictive & Presymptomatic Testing Research Report:

An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.

To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.

Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year

Identifying DROC in the current market and their impact in altering the market dynamics.

Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.

Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.

• BioAxis
• Genomic diagnosis
• Quest Diagnostics, Inc.
• Positive Bioscience
• Color Genomics